CNBC World

Novo Nordisk stock falls after raised forecast fails to change the debate over its obesity business

Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.

This is a short WorldPing brief. The full report was published by CNBC World.

Read the full report at CNBC World

Related news